Treatment with the combination of the CD47-targeting antibody magrolimab and azacitidine induced high response rates, particularly in patients with myelodysplastic syndromes. David A. Sallman, MD, discusses findings from an ongoing phase Ib trial.
Recent Articles
Editor’s Corner: At World’s End
Just before the first deaths from the SARS-CoV-2 virus were reported in the U.S. and the Commonwealth of Massachusetts declared a state of emergency,...
Aveo and Biodesix Stop Trials of Ficlatuzumab for Acute Myeloid Leukemia
Aveo and Biodesix have decided to stop all trials of their hepatocyte growth factor inhibitory antibody ficlatuzumab for acute myeloid leukemia (AML), citing the...
FDA Grants Orphan Drug Designations to Avatrombopag and CLR 131
The FDA has granted orphan drug designations to two therapies for hematologic conditions.
The oral thrombopoietin receptor agonist avatrombopag is indicated for the treatment of...
When, and How, Can We Safely Relax Coronavirus Lockdown Measures?
While the U.S. struggles to control the COVID-19 outbreak and public health experts urge government officials to uphold social-distancing measures, global epidemiology modelers and...
Could Antibody Blood Tests Determine Who’s Immune to the Coronavirus?
A new blood test could determine who may have immunity to COVID-19 by identifying antibodies in people who have already been infected but were...
Current Issue
April 2020, Volume 6, Issue 5
This issue examines current immunization guidelines for patients with hematologic disorders, considers medical education amid the coronavirus pandemic, and more.
